Physician profile
Todd Brooks
NPI 1598292724
$8,753.38
in general payments reported to CMS, 2019-2025
23 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $898 · 2022: $1,574 · 2023: $2,345 · 2024: $2,335 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,709 · Education: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,708.55 |
| Education | $572.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,087.29 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,868.99 | 2021-2025 | |
| Lilly USA, LLC | $988.30 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $934.77 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $674.91 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $553.99 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $385.09 | 2022-2024 | Sotyktu |
| Ucb, INC. | $314.05 | 2023-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $178.98 | 2022-2023 | |
| Pfizer INC. | $178.04 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $134.60 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $95.44 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $92.77 | 2021 | |
| Arcutis Biotherapeutics, INC. | $92.60 | 2023-2025 | Zoryve |
| Incyte Corporation | $41.55 | 2025 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23.13 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Galderma Laboratories, L.P. | $21.94 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.33 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.52 | 2023 | Spevigo |
| Sandoz INC. | $15.67 | 2023 | Hyrimoz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.14 | 2021 | |
| Dermavant Sciences, INC. | $11.84 | 2022 | |
| Genentech USA, INC. | $10.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.